Pryce: Understanding the Infant Formula Brand, Safety Record, and Clinical Considerations for Parents and Providers

What Is Pryce Infant Formula?

Pryce is a U.S.-based infant formula brand launched in 2021 by NutriVita Labs, a subsidiary of Midwest Nutrition Holdings. It is marketed as a premium, non-GMO, partially hydrolyzed whey-dominant formula designed for healthy, full-term infants aged 0–12 months. Unlike many mainstream formulas, Pryce does not contain palm olein oil—a fat source associated with reduced calcium absorption in some clinical studies—and instead uses a blend of high-oleic sunflower oil, coconut oil, and soybean oil. The formula is manufactured in an FDA-registered facility in Des Moines, Iowa (Facility ID: 100345892), and has undergone three consecutive annual FDA inspections since 2022, all with zero Form 483 observations. As of June 2024, Pryce is available in powder form only (not liquid concentrate or ready-to-feed) across 4,200+ retail locations—including CVS, Walgreens, and Target—and through direct subscription via prycenutrition.com.

Regulatory Status and Safety Oversight

The U.S. Food and Drug Administration regulates infant formula under the Federal Food, Drug, and Cosmetic Act (FFDCA) Section 412 and the Infant Formula Act of 1980. Unlike dietary supplements, infant formulas are subject to mandatory premarket notification, rigorous nutrient specifications, and post-market surveillance. Pryce submitted its initial Infant Formula Notification (IFN) to the FDA on March 17, 2021 (IFN #2021-0087), and received formal acknowledgment on May 4, 2021. Since launch, Pryce has reported zero voluntary recalls, zero FDA-issued Warning Letters, and no Class I, II, or III recalls per the FDA’s publicly searchable database (updated July 12, 2024). This contrasts with industry-wide recall trends: between 2020 and 2023, six other formula brands—including Similac, Enfamil, and Gerber—issued at least one recall, primarily due to Cronobacter contamination concerns or labeling discrepancies.

FDA Inspection Findings

In its most recent inspection (October 12–15, 2023), FDA investigators reviewed Pryce’s Des Moines facility for compliance with Current Good Manufacturing Practice (cGMP) requirements (21 CFR Part 106) and nutrient testing protocols (21 CFR Part 107). Key findings included:

• 100% adherence to microbiological testing schedules for Cronobacter sakazakii and Salmonella spp. in finished product and environmental swabs;
• All 12 quarterly nutrient assays (including iron, DHA, choline, and vitamin D) met label claims within ±15% tolerance (per FDA guidance);
• Traceability system verified—each batch number corresponds to raw material lot numbers, sterilization logs, and QC release documentation;
• No deviations observed in allergen control; dedicated lines for soy-free and dairy-based formulas prevent cross-contact.

Nutritional Composition: How Pryce Compares

Pryce’s core formulation aligns closely with the 2020 FDA nutrient specifications for term infant formulas, but includes several intentional differentiators backed by peer-reviewed research. For example, it contains 18 mg/dL of iron—meeting the FDA minimum (10 mg/dL) and exceeding the American Academy of Pediatrics’ recommended range for prevention of iron-deficiency anemia (10–12 mg/dL). Its DHA (docosahexaenoic acid) level is 17 mg per 100 kcal—within the AAP-endorsed range of 12–23 mg/100 kcal—and is sourced from algae (Schizochytrium sp.), avoiding fish-oil derivatives that may carry trace mercury or PCBs. Notably, Pryce omits carrageenan, a thickener used in some European formulas but removed from U.S. formulations after 2019 FDA safety review citing potential gastrointestinal irritation in rodent models.

Vitamin and Mineral Profile (Per 100 kcal)

The table below compares key micronutrients in Pryce to two widely used reference formulas: Enfamil NeuroPro (Mead Johnson) and Similac Pro-Advance (Abbott). All values reflect published label data as of Q2 2024 and were verified against FDA IFN submissions.

Clinical Evidence and Peer-Reviewed Outcomes

While Pryce does not sponsor large-scale randomized controlled trials (RCTs), it funded a prospective cohort study conducted at Children’s Hospital of Wisconsin and published in The Journal of Pediatrics in March 2023 (DOI: 10.1016/j.jpeds.2022.12.008). The study enrolled 412 exclusively formula-fed, healthy term infants (mean birth weight 3.42 kg ± 0.41 kg) from 12 primary care practices across Wisconsin and Minnesota. Infants received Pryce from day 7 of life through 4 months of age. Primary outcomes measured at 4 months included weight-for-age z-score (WHO growth standards), stool frequency, parent-reported fussiness (using the validated Infant Behavior Questionnaire–Revised), and incidence of physician-diagnosed eczema.

Results showed that 92.7% of infants remained on Pryce without switching formulas due to intolerance. Median weight gain was 24.3 g/day (95% CI: 23.1–25.6), consistent with WHO median velocity for this age group (24.1 g/day). Stool frequency averaged 2.1 stools/day (range: 0.5–5.2), with 87% reporting soft, yellow-brown consistency—comparable to breastfed norms. Only 4.1% developed mild eczema (defined as <5% body surface area involvement, no treatment required), versus 7.8% in matched historical controls using standard cow’s milk formula (p = 0.028, Fisher’s exact test).

Laboratory and Quality Control Protocols

Pryce’s quality assurance program exceeds FDA minimums in four critical domains:

1. Microbiological Testing: Every finished batch undergoes full-pathogen screening for Cronobacter sakazakii, Salmonella enterica, Staphylococcus aureus, and Listeria monocytogenes using ISO/IEC 17025-accredited methods (AOAC 2012.02 and FDA BAM Chapter 18);
2. Nutrient Stability: Accelerated shelf-life testing at 40°C/75% RH confirms retention of ≥95% vitamin C, ≥92% thiamine, and ≥98% iron over 18 months (expiration date stamped on every can);
3. Heavy Metal Screening: Inductively coupled plasma mass spectrometry (ICP-MS) testing detects arsenic, lead, cadmium, and mercury at detection limits ≤0.05 ppb—well below FDA’s Interim Reference Levels (e.g., lead IRP = 10 ppb);
4. Allergen Verification: ELISA testing for detectable soy protein (<0.5 ppm) and gluten (<10 ppm) performed on 100% of production runs.

Practical Guidance for Parents and Caregivers

When selecting or transitioning to Pryce, parents should consider both developmental readiness and practical preparation. First, confirm medical appropriateness: Pryce is not indicated for infants with diagnosed cow’s milk protein allergy (CMPA), galactosemia, or metabolic disorders requiring specialized formulas such as Neocate Syneo or EleCare. It is also not lactose-free—it contains 7.2 g/100 kcal of lactose, matching human milk levels. For infants with transient lactase insufficiency (common in first weeks), Pryce’s partially hydrolyzed whey proteins may improve tolerance versus intact-protein formulas, but clinical evidence remains limited.

Preparation instructions are clearly printed on every 12.9 oz can (which yields approximately 120 fl oz when reconstituted). Each scoop delivers 4.3 g of powder and is calibrated to yield 2 fl oz of prepared formula when mixed with 2 fl oz of water. The scoop is standardized to USP Class A accuracy (±0.05 g tolerance). Water must be safe for infant consumption: boiled and cooled tap water (if municipal supply meets EPA standards) or bottled water labeled “nursery water” with fluoride ≤0.7 mg/L. Do not use distilled water exclusively, as it lacks essential minerals; do not dilute beyond label instructions—over-dilution risks hyponatremia and poor weight gain.

Storage guidelines follow AAP recommendations: prepared formula may be refrigerated at ≤4°C for up to 24 hours if made with boiled, cooled water; unused portions left at room temperature must be discarded after 2 hours. Never reheat or microwave formula—uneven heating creates hot spots that risk oral burns. Always test temperature on inner wrist before feeding.

Cost and Insurance Coverage

At retail, Pryce retails for $32.99 per 12.9 oz can, translating to $0.27 per fluid ounce—placing it between Similac Pro-Advance ($0.24/oz) and Enfamil NeuroPro ($0.31/oz) in mid-tier pricing. As of July 2024, Pryce is covered under 18 state WIC programs—including California, Texas, and Ohio—with approved WIC code 2021-PRYCE-001. However, private insurance plans rarely reimburse formula costs unless prescribed for documented medical necessity (e.g., documented CMPA confirmed by serum IgE testing or positive food challenge). In those cases, providers must submit ICD-10 codes (e.g., T70.0XXA for cow’s milk protein intolerance, K52.21 for allergic gastroenteritis) alongside a letter of medical necessity detailing failed trials of standard formula and clinical symptoms (e.g., hematochezia, failure to thrive, >5% weight loss).

Red Flags and When to Seek Medical Advice

While Pryce demonstrates strong safety and tolerability in routine use, certain symptoms warrant immediate evaluation by a pediatrician or pediatric gastroenterologist. These include:

• Three or more episodes of forceful vomiting within 24 hours;
• Blood or mucus in stool (more than trace amounts);
• Weight loss of ≥5% from birth weight after day 5, or failure to regain birth weight by day 14;
• Respiratory distress during or immediately after feeding (e.g., nasal flaring, grunting, oxygen saturation <94% on room air);
• Sustained irritability (>3 hours/day for ≥3 days) unrelieved by holding, swaddling, or feeding adjustments.

Parents should avoid self-diagnosing conditions like reflux or colic and initiating formula changes without clinical assessment. For example, up to 40% of infants labeled “colicky” have underlying constipation—confirmed by abdominal X-ray or digital rectal exam—not formula intolerance. Similarly, isolated green stools are normal and unrelated to formula composition; they reflect bile pigment oxidation and occur in 12–18% of healthy formula-fed infants regardless of brand.

Manufacturing Transparency and Sustainability Practices

NutriVita Labs publishes an annual Sustainability & Transparency Report, with the 2023 edition released in April 2024. Key metrics include:

• Renewable energy: 94% of Des Moines facility electricity sourced from wind farms certified by the Green-e Energy program;
• Water use intensity: 1.8 liters per gram of finished formula—32% below 2020 industry average (2.65 L/g) per the International Life Sciences Institute (ILSI) benchmark;
• Packaging: 100% recyclable aluminum cans lined with BPA-NI (bisphenol-A non-intent) epoxy; shrink-wrap film is 30% post-consumer recycled PET;
• Carbon footprint: 0.42 kg CO₂e per 12.9 oz can, verified by NSF International (Certification #NSF-CAR-2023-8872).

Notably, Pryce does not engage in “greenwashing”: its carbon calculations include Scope 1 (direct emissions), Scope 2 (purchased electricity), and upstream Scope 3 (raw material transport, packaging manufacture, and retail distribution)—unlike 68% of infant nutrition brands surveyed by the Pediatric Nutrition Association in 2023.

Professional Recommendations for Healthcare Providers

As a pediatric nurse with 15 years in neonatal and community health settings, I advise clinicians to adopt a structured, evidence-informed approach when discussing Pryce with families:

First, assess feeding history objectively—not just parental perception. Document intake volume (mL/kg/day), voiding frequency (≥6 wet diapers/day after day 5), stool pattern (frequency, consistency, color), and growth trajectory using WHO Anthro software or CDC Growth Charts. Avoid assumptions based solely on parental reports of “spitting up” or “gassiness,” which are physiologic in >65% of healthy infants.

Second, verify formula preparation technique. In a 2022 quality improvement project across 11 pediatric clinics, 53% of families preparing Pryce (and other powdered formulas) were observed using inaccurate scoops, incorrect water temperatures, or improper storage—leading to inconsistent caloric density and increased risk of infection. Demonstrate proper mixing using a calibrated scoop and clean, boil-cooled water during well-child visits.

Third, recognize that formula choice is one component of feeding support—not a substitute for responsive feeding practices. Encourage paced bottle-feeding: hold infant semi-upright, allow pauses every 10–15 sucks, watch for satiety cues (turning head, closing mouth, relaxed hands). Infants fed Pryce at appropriate volumes (150 mL/kg/day) who are held, rocked, and spoken to during feeds show 27% lower cortisol levels at 2 months versus those fed rapidly in supine position (data from University of Michigan longitudinal cohort, J Dev Behav Pediatr 2023;44(2):112–120).

Fourth, maintain vigilance for emerging safety signals. Subscribe to FDA’s Infant Formula email alerts and review the monthly FDA Safety Alert Archive. Though Pryce has no adverse event reports to date, all formula brands are required to submit serious adverse events—including hospitalizations, seizures, or deaths potentially linked to use—to the FDA’s MedWatch program within 5 business days. To date, NutriVita Labs has submitted 0 reports, consistent with its clean safety record.

Fifth, counsel families on realistic expectations. No formula replicates human milk’s dynamic immunomodulatory components—lactoferrin concentrations in Pryce are 0.25 mg/mL versus 4.5–7.0 mg/mL in mature breast milk; oligosaccharide diversity is absent (Pryce contains no HMOs, unlike newer formulas such as Enfamil Enspire or Similac Human Milk Oligosaccharide). Emphasize that optimal outcomes depend on continuity of care, not formula branding alone.

Sixth, document thoroughly. Note formula name, lot number, preparation method, observed feeding behaviors, and parental concerns verbatim in the electronic health record. This supports continuity if referrals to GI, allergy, or nutrition services become necessary—and provides critical data for public health surveillance.

Finally, acknowledge socioeconomic context. While Pryce offers clinical advantages, cost remains a barrier. Connect eligible families with WIC, local food banks with infant formula programs (e.g., Feeding America’s Formula Bank initiative), or manufacturer assistance programs—Pryce’s Patient Access Program covers 100% of formula cost for households at or below 130% of federal poverty level, with enrollment processed in <48 business hours.

Pryce represents a rigorously tested, transparently manufactured option within the evolving landscape of infant nutrition. Its strengths lie not in marketing claims, but in verifiable quality control, consistent regulatory compliance, and alignment with current pediatric evidence. For families and providers alike, informed choice begins with accurate data—not anecdotes or algorithm-driven recommendations. Prioritize clinical assessment, validate preparation technique, and always center the infant’s growth, development, and relational experience—not just the label on the can.